Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MRMNASDAQ:SRZNNASDAQ:TNXPNASDAQ:XWEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRMMEDIROM Healthcare Technologies$0.87-4.8%$0.68$0.34▼$8.39$4.86M0.46632,355 shs9,007 shsSRZNSurrozen$8.00-4.2%$10.54$6.00▼$18.17$26.25M0.6921,022 shs16,646 shsTNXPTonix Pharmaceuticals$19.19+1.9%$18.15$6.76▼$672.00$123.49M1.63800,860 shs376,926 shsXWELXWELL$0.86-2.3%$0.89$0.70▼$2.70$4.52M1.0150,352 shs278,903 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRMMEDIROM Healthcare Technologies0.00%+7.68%-13.75%+0.46%-83.38%SRZNSurrozen0.00%-16.16%-6.02%-16.50%-19.71%TNXPTonix Pharmaceuticals0.00%-5.80%+11.61%+57.79%-96.57%XWELXWELL0.00%+9.73%+13.43%-25.42%-51.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMRMMEDIROM Healthcare TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ASRZNSurrozen3.5546 of 5 stars3.55.00.00.01.05.00.6TNXPTonix Pharmaceuticals2.4788 of 5 stars3.52.00.00.02.11.71.3XWELXWELL1.3152 of 5 stars0.05.00.00.03.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRMMEDIROM Healthcare Technologies 4.00Strong BuyN/AN/ASRZNSurrozen 3.00Buy$38.50381.25% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.002,948.46% UpsideXWELXWELL 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MRM, XWEL, SRZN, and TNXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025SRZNSurrozenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/2/2025SRZNSurrozenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.003/20/2025TNXPTonix PharmaceuticalsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRMMEDIROM Healthcare Technologies$8.30B0.00$0.58 per share1.49$0.31 per share2.81SRZNSurrozen$10.66M2.46N/AN/A$18.39 per share0.44TNXPTonix Pharmaceuticals$10.09M12.23N/AN/A$5,751.80 per share0.00XWELXWELL$33.90M0.13N/AN/A$5.02 per share0.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRMMEDIROM Healthcare Technologies$820KN/A0.00∞N/AN/AN/AN/AN/ASRZNSurrozen-$43.04M-$24.96N/AN/AN/AN/A-120.51%-54.68%5/14/2025 (Estimated)TNXPTonix Pharmaceuticals-$116.66M-$2,535.85N/AN/AN/A-1,197.86%-163.95%-118.88%5/12/2025 (Estimated)XWELXWELL-$27.74M-$3.62N/A∞N/A-46.82%-88.27%-43.24%5/13/2025 (Estimated)Latest MRM, XWEL, SRZN, and TNXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 millionN/A5/9/2025Q1 2025SRZNSurrozen-$1.09-$3.13-$2.04-$7.43N/A$0.98 million4/15/2025Q1 2025XWELXWELLN/A-$1.55N/A-$1.55N/A$7.47 million3/31/2025Q4 2024SRZNSurrozen-$2.54-$9.10-$6.56-$9.10N/A$0.66 million3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRMMEDIROM Healthcare TechnologiesN/AN/AN/AN/AN/ASRZNSurrozenN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/AXWELXWELLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRMMEDIROM Healthcare TechnologiesN/A0.340.29SRZNSurrozenN/A7.407.40TNXPTonix Pharmaceuticals0.073.332.81XWELXWELLN/A1.981.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRMMEDIROM Healthcare TechnologiesN/ASRZNSurrozen66.57%TNXPTonix Pharmaceuticals82.26%XWELXWELL8.67%Insider OwnershipCompanyInsider OwnershipMRMMEDIROM Healthcare Technologies40.24%SRZNSurrozen45.18%TNXPTonix Pharmaceuticals0.03%XWELXWELL8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRMMEDIROM Healthcare Technologies4805.59 million2.95 millionNot OptionableSRZNSurrozen803.28 million1.84 millionNot OptionableTNXPTonix Pharmaceuticals506.44 million1.87 millionNot OptionableXWELXWELL3605.26 million4.98 millionNo DataMRM, XWEL, SRZN, and TNXP HeadlinesRecent News About These CompaniesXWELL Inc. appoints new auditor, cites internal control issuesApril 23, 2025 | investing.comXWELL, Inc. Reports 13% Revenue Growth and Plans Expansion into Wellness Sector with New Brand StrategyApril 15, 2025 | quiverquant.comXWELL Reports Fiscal Year 2024 ResultsApril 15, 2025 | globenewswire.comXWELL shareholders approve incentive plan amendmentApril 13, 2025 | uk.investing.comXWELL Expands Into Medical Spa Market With Strategic AcquisitionsMarch 15, 2025 | nasdaq.comXwell announces plan for strategic investment in medical spasMarch 13, 2025 | markets.businessinsider.comXWELL, Inc. Announces Acquisition Plans for Medical Spas to Expand Wellness and Beauty OfferingsMarch 13, 2025 | quiverquant.comXWELL Announces Plan for Strategic Investment in Medical Spas to Advance Wellness and Beauty OfferingsMarch 13, 2025 | globenewswire.comCentri Names Presenting Companies for Capital Conference at Nasdaq on April 22March 7, 2025 | finance.yahoo.comXWELL, Inc. (XWEL) Stock Price, News, Quote & History - Yahoo FinanceMarch 4, 2025 | finance.yahoo.comXwell files to sell 1.05M shares of common stock for holdersFebruary 8, 2025 | markets.businessinsider.comXWEL stock touches 52-week low at $1.25 amid market fluctuationsJanuary 16, 2025 | msn.comXWELL, Inc. Closes $4 Million Private Placement of Series G Convertible Preferred StockJanuary 15, 2025 | quiverquant.comXWELL Announces Closing of $4 Million Private Placement Consisting of Convertible Preferred Stock and WarrantsJanuary 15, 2025 | globenewswire.comXwell CFO Suzanne Scrabis departs, Ian Brown succeedsJanuary 8, 2025 | markets.businessinsider.comXWELL Announces Senior Leadership Appointments and ChangesJanuary 7, 2025 | globenewswire.comXwell Inc (XWEL) Stock: Surpassing Expectations in the Market?December 17, 2024 | bovnews.comXWELL Unifies Wellness Offerings to Boost GrowthDecember 5, 2024 | markets.businessinsider.comXWELL, Inc. CEO Ezra Ernst Shares 2025 Business Objectives Focused on Unifying Wellness Brand and Accelerating GrowthDecember 5, 2024 | quiverquant.comOpen Letter to XWELL Shareholders from CEO Ezra ErnstDecember 5, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRM, XWEL, SRZN, and TNXP Company DescriptionsMEDIROM Healthcare Technologies NYSE:MRM$0.87 -0.04 (-4.83%) Closing price 03:59 PM EasternExtended Trading$0.83 -0.04 (-4.94%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MEDIROM Healthcare Technologies Inc. provides holistic healthcare services in Japan. It operates in three segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty. The Relaxation Salon segment owns and franchises relaxation salons, which provide finger-pressure style bodywork therapy, stretch therapy, and posture and joint alignment, as well as physical therapy elements; and various individual services, including anti-fatigue therapy, athletic support therapy, slim-down therapy, and reflexology. This segment operates relaxation salons under the Re.Ra.Ku and Ruam Ruam brands. The Digital Preventative Healthcare segment offers government-sponsored Specific Health Guidance program, utilizing Lav, an on-demand health monitoring smartphone application and MOTHER Bracelet for fitness applications; and preventative healthcare services utilizing nutritionists and health nurses. The Luxury Beauty segment manages and operates hair salons under the ZACC brand name. MEDIROM Healthcare Technologies Inc. also operates Re.Ra.Ku College that offers continuing training for franchise owners, home office staff, and salon staff covering topics, such as customer service, salon operations, and relaxation techniques. The company was formerly known as MEDIROM Inc. and changed its name to MEDIROM Healthcare Technologies Inc. in March 2020. MEDIROM Healthcare Technologies Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.Surrozen NASDAQ:SRZN$8.00 -0.35 (-4.19%) Closing price 04:00 PM EasternExtended Trading$8.06 +0.06 (+0.75%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.Tonix Pharmaceuticals NASDAQ:TNXP$19.19 +0.36 (+1.91%) Closing price 04:00 PM EasternExtended Trading$19.16 -0.03 (-0.13%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.XWELL NASDAQ:XWEL$0.86 -0.02 (-2.27%) Closing price 03:56 PM EasternExtended Trading$0.86 0.00 (0.00%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XWELL, Inc. provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. The Treat segment provides access to wellness services for travelers at on-site centers, consisting of self-guided yoga, meditation, and low impact weight exercises programs. The company offers its services through stores, kiosks, and online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
